Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Nat Clin Pract Oncol. 2008 Aug;5(8):487-91. doi: 10.1038/ncponc1157. Epub 2008 Jun 17.

Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy.

Author information

  • 1Department of Neurology, Massachusetts General Hospital, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA. splotkin@partners.org

Abstract

BACKGROUND:

A 48-year-old man presented to a neurologist with complaints of bilateral hearing loss and tinnitus. The patient was a member of a large family affected by neurofibromatosis type 2 and first noted hearing loss 10 years before presentation.

INVESTIGATIONS:

Medical and neurological examination, MRI scan of the brain and spinal cord, pure-tone audiometry, NU-6 monosyllabic word test with phoneme scoring, City University of New York topic-related sentences test, noise/voice test of minimal auditory capability battery.

DIAGNOSIS:

Progressive neurofibromatosis-type-2-related vestibular schwannomas.

MANAGEMENT:

Annual cranial MRI and audiology, surgical resection of right vestibular schwannoma, high-power behind-the-ear hearing aid, erlotinib therapy for progressive left vestibular schwannoma.

PMID:
18560388
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk